601607 On Other Exchanges
Symbol
Exchange
601607 is not on other exchanges.

shanghai pharmaceuticals-a (601607) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
--
EPS TTM
--
Shares Outstanding
--
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SHANGHAI PHARMACEUTICALS-A (601607)

Related News

No related news articles were found.

shanghai pharmaceuticals-a (601607) Related Businessweek News

No Related Businessweek News Found

shanghai pharmaceuticals-a (601607) Details

Shanghai Pharmaceuticals Holding Co., Ltd., together with its subsidiaries, researches, develops, manufactures, distributes, and retails pharmaceutical and healthcare products in the People’s Republic of China. It operates through Production, Distribution, Retail, and Others segments. The company offers a range of products, including chemical and bio-pharms, modern Chinese medicine, healthcare products, medical devices, etc. in various therapeutic areas, such as cardiovascular, systemic anti-infections, digestive system and immune-metabolism, neuropsychiatric, and antineoplastic, as well as anti-tumor and immunomodulatory, musculo-skeletal, respiratory, genito-urinary and sex hormone, blood and blood-forming organ, neurological, and other therapeutic areas. It provides its products in various dosage forms that include tablets, capsules, powder, mini-volume injections, eye-drops, inhalants, coagulants, etc. The company also engages in the provision of pharmaceutical distribution, warehousing, logistics, and other value-added pharmaceutical supply chain solutions and related services to pharmaceutical manufacturers and dispensers, such as hospitals, distributors, and retail pharmacies. In addition, it operates a network of retail pharmacy stores, as well as engages in consulting service, assets management, investment holding operations, etc. Further, the company manufactures and trades medicines and medical equipment; and rents properties, as well as wholesales chemicals and active pharmaceutical ingredients. As of December 31, 2015, it had 1,769 chain retail pharmacies under its brand family, including 1,167 directly operated pharmacies. The company was incorporated in 1994 and is headquartered in Shanghai, the People's Republic of China. Shanghai Pharmaceuticals Holding Co., Ltd. is a subsidiary of Shanghai Pharmaceutical (Group) Co., Ltd.

41,173 Employees
Last Reported Date: 03/18/16
Founded in 1994

shanghai pharmaceuticals-a (601607) Top Compensated Officers

President, Executive Director and Convener of...
Total Annual Compensation: CNY2.0M
Compensation as of Fiscal Year 2015.
shanghai pharmaceuticals-a
Shanghai Pharmaceuticals Holding Co., Ltd. Presents at UBS Greater China Conference 2017, Jan-09-2017

Shanghai Pharmaceuticals Holding Co., Ltd. Presents at UBS Greater China Conference 2017, Jan-09-2017 . Venue: China Hall, 3/F, Grand Tower, Shangri-La Shanghai Pudong, Shanghai 738, China.

Shanghai Pharmaceuticals Holding Co., Ltd. Announces Consolidated and Parent Earnings Results for the Third Quarter and Nine Months Ended September 30, 2016

Shanghai Pharmaceuticals Holding Co., Ltd. announced consolidated and parent earnings results for the third quarter and nine months ended September 30, 2016. For the quarter, on consolidated basis the company reported total revenue of operation of RMB 30,821,502,833.13 compared with RMB 28,090,262,686.33 for the same period a year ago. Operating profit was RMB 1,004,087,980.74 compared with RMB 894,200,823.80 for the same period a year ago. Net profit attributable to owners of the parent company was RMB 724,710,787.01 compared with RMB 644,802,072.38 for the same period a year ago. Diluted earnings per share was RMB 0.2695 against 0.2398 for the same period a year ago. For the nine months, on consolidated basis the company reported total revenue of operation of RMB 90,516,860,848.95 compared with RMB 79,040,339,101.51 for the same period a year ago. Operating profit was RMB 3,311,719,543.32 compared with RMB 2,910,110,117.25 for the same period a year ago. Net profit attributable to owners of the parent company was RMB 2,457,168,751.22 compared with RMB 2,178,822,695.48 for the same period a year ago. Basic and diluted earnings per share was RMB 0.9138 compared with RMB 0.8103 for the same period a year ago. Net cash flows from operating activities was RMB 1,309,579,871.88 compared with RMB 670,197,580.67 for the same period a year ago. Cash paid to acquire fixed assets, intangible assets and other long-term assets was RMB 1,316,173,938.26 compared with RMB 1,050,552,482.69 for the same period a year ago. The company reported Weighted average return on net assets 7.96%. For the quarter, on parent basis the company reported operating revenue of RMB 2,376,222.66 compared with RMB 2,584,599.16 for the same period a year ago. Operating profit was RMB 527,658,537.74 compared with RMB 256,022,243.23 for the same period a year ago. Net profit was RMB 530,763,171.01 compared with RMB 277,243,125.66 for the same period a year ago. For the nine months, on parent basis the company reported operating revenue of RMB 5,602,702.87 compared with RMB 23,801,991.63 for the same period a year ago. Operating profit was RMB 1,096,886,268.13 compared with RMB 868,526,804.45 for the same period a year ago. Net profit was RMB 1,123,058,024.16 compared with RMB 906,835,617.50 for the same period a year ago. Net cash flows from operating activities was RMB 41,070,140.04 compared with RMB 116,663,030.88 for the same period a year ago. Cash paid to acquire fixed assets, intangible assets and other long-term assets was RMB 24,025,094.56 compared with RMB 32,274,459.14 for the same period a year ago.

Shanghai Pharmaceuticals Holding Co., Ltd. Appoints Zhou Jun as Chairman of the Board and Member of Nomination Committee

Shanghai Pharmaceuticals Holding Co., Ltd. announced that Mr. Zhou Jun, a newly elected non-executive director of the company, has been appointed as the chairman of the Board of the company and a member of the nomination committee of the Board with effect from 20 October 2016 until the expiry of the term of the sixth session of the Board. He has over 20 years of professional experience in securities, merger and acquisition, finance, real estate, project planning and corporate management. He is currently the chairman of the Board and a non-executive director of the company and does not hold any directorship in the subsidiaries of the company. He has been a president and an executive director of Shanghai Industrial Investment (Holdings) Co., Ltd. since September 2016 and May 2012, respectively. He has also been the vice chairman and the chief executive officer since August 2016.

 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

601607 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 601607.
View Industry Companies
 

Industry Analysis

601607

Industry Average

Valuation 601607 Industry Range
Price/Earnings 17.4x
Price/Sales 0.5x
Price/Book 1.7x
Price/Cash Flow 12.4x
TEV/Sales 0.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact SHANGHAI PHARMACEUTICALS-A, please visit www.sphchina.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.